PharmaFocus Today – Page 21 – media

Biopharma Funding Rounds Advance Clinical Development of Novel Therapy and Treatment Solutions

The momentum of funding in biopharmaceutical continues, as organizations focus on advancing R&D for respective leading therapy and treatment candidates undergoing clinical testing. Companies such as Veradermics Inc., Peptilogics, and BridGene Biosciences all recently announced the completion of major funding rounds, helping to advance clinical testing. Veradermic Incorporated Veradermics announced the completion of an oversubscribed $150 million Series C financing round.1 The funding is expected to support the registrational development and planned New Drug Application submission for Veradermics’ lead investigational product, VDPHL01, which holds potential to be the first and only extended-release oral minoxidil treatment designed specifically for hair regrowth in women and men.1 According to a press release from Veradermic, the collected capital will be invested in advancing and completing the ongoing Phase III trials for its lead candidate. SR One led the financing round and received a mixed participation from both new and current investors, including the following. ...
- Source: drugdu
- 76
- October 17, 2025
Another Chinese anti-cancer drug has become a “billion-dollar drug,” with sales exceeding $1.3 billion this year.

In the global biopharmaceutical industry, drugs with annual revenue exceeding $1 billion are often called “blockbuster” drugs. Following BeiGene ‘s Zanubrutinib, another domestically produced cancer drug has successfully crossed this sales threshold. Recently, KingSher Biotech (01548.HK) announced the latest sales of its associate company Legend Biotech’s Carvykti (Cedaciolence). According to statistics, Cedar Rapids’ sales in the third quarter were US$524 million. Including the sales of US$369 million in the first quarter and US$439 million in the second quarter, the total sales amount this year has reached US$1.332 billion. In December 2017, domestic innovative drugsLegend Biotech and multinational pharmaceutical company Johnson & JohnsonThe companies signed an exclusive global license and collaboration agreement to develop and commercialize Cedars-Sinai. Legend Biotech will be responsible for market development and commercialization in Greater China, while Johnson & Johnson will lead the rest of the world. Legend Biotech and Johnson & Johnson will share revenues 7:3 ...
- Source: drugdu
- 90
- October 17, 2025
Junshi Biosciences’ Phase II/III clinical trial application for JS207 as a neoadjuvant treatment for patients with non-small cell lung cancer has been approved by the FDA.

Beijing Business Daily (Reporter Ding Ning) On the evening of October 16, Junshi Biosciences (688180) issued an announcement stating that the company’s product, a recombinant humanized anti-PD-1 and VEGF bispecific antibody (code: JS207), compared with nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, alterable driver gene (AGA)-negative non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration (FDA) for its clinical trial application. The announcement shows that JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody independently developed by the company, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively blocking the binding of PD-1 to PD-L1 and PD-L2, and inhibiting the binding of VEGF to its receptors. JS207 has immunotherapy effects.The therapeutic properties of drugs and anti-angiogenic drugs can inhibit the proliferation of vascular endothelial cells by neutralizing VEGF, ...
- Source: drugdu
- 74
- October 17, 2025
Signs licensing agreement with Roche, with milestone payments of up to $1.45 billion

On October 17, Hansoh Pharmaceutical (03692) announced that it had entered into a licensing agreement with F. Hoffmann-La Roche Ltd. (a subsidiary of Roche). Under the agreement, Hansoh Pharmaceutical ‘s wholly-owned subsidiaries, Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd., will grant the licensee an exclusive global license (excluding Mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize HS-20110. Hansoh Pharma will receive an upfront payment of $80 million and is eligible to receive up to $1.45 billion in milestone payments based on the product’s development, regulatory approval, and commercialization progress, as well as tiered royalties on potential future product sales. The product is an investigational CDH17-targeting antibody-drug conjugate (ADC) currently in global Phase I clinical trials in China and the United States for the treatment of colorectal cancer and other solid tumors. The Board of Directors believes that this license agreement is ...
- Source: drugdu
- 86
- October 17, 2025
Kelun Biotech’s anti-cancer drug received approval for a new indication, contributing over 90% of its sales revenue in the first half of the year.

According to the Red Star Capital Bureau on October 13, Kelun Biotech (06990.HK) announced yesterday evening that its drug Lukang Satuzumab (Jiatailai®) has been approved by the National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) gene mutations that have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Kelun Botai’s parent company Kelun Pharmaceutical(002422.SZ) told the Red Star Capital Bureau that the approval of this indication means that patients can directly use Lucansatumomab without chemotherapy after subsequent progress of EGFR-TKI treatment, which is conducive to expanding the scope of application for patients. It is reported that Lukangsatuzumab is a core product of Kelun Biotech. In the first half of this year, over 90% of Kelun Biotech’s pharmaceutical sales revenue came from Lukangsatuzumab, and BD (business development) ...
- Source: drugdu
- 65
- October 17, 2025
Eli Lilly’s new oral medication offers significant glucose control benefits, potentially improving patient convenience and compliance.

Drug innovation is becoming an important force in promoting the improvement of diabetes treatment level .The company announced that its investigational oral GLP-1 drug orforglipron achieved the primary endpoint and all key secondary endpoints in two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5, reaffirming its potential as a basic treatment for type 2 diabetes. The ACHIEVE-2 study directly addresses the vast patient population whose glycemic control remains poor despite classic first-line treatments. It conducted a head-to-head evaluation of the efficacy and safety of oral orforglipron compared with dapagliflozin in adults with type 2 diabetes whose glycemic control is inadequate despite metformin treatment. The new drug demonstrated significant superiority over dapagliflozin in lowering A1C, a key marker of glycated hemoglobin, achieving a 1.7% reduction in A1C compared to a 0.8% reduction with dapagliflozin. This is the second head-to-head trial in this series by Eli Lilly and Company, following the previous head-to-head ...
- Source: drugdu
- 68
- October 17, 2025
Tangning Tongluo Tablets approved for clinical trials for type 2 diabetes

　　China Securities Intelligent Finance Guizhou Bailing(002424) announced on the evening of October 15 that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., received the “Notice of Approval of Drug Clinical Trial” approved and issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo Tablets submitted by Bailing Yuxiu was approved, and it was agreed that this product would be used for clinical trials in type 2 diabetes. 　　The announcement indicates that this product, which received clinical trial approval in 2024 for non-proliferative diabetic retinopathy (yin deficiency, internal heat, and eye meridian stasis), is currently applying to add an indication for type 2 diabetes (damp-heat accumulation syndrome) during clinical trials. The information states that Tangning Tongluo Tablets were prepared by a medical institution in Guizhou Province, and summary reports from three previous clinical studies have been provided. This Phase II clinical trial will fully explore ...
- Source: drugdu
- 148
- October 16, 2025
TQ-B3234 Capsules, a “selective MEK1/2 inhibitor,” receives Breakthrough Therapy Designation

On October 15, Sino Biopharmaceutical (01177) issued an announcement, announcing that the national Class 1 new drug TQ-B3234 capsules, a “selective MEK1/2 inhibitor” developed by it, has been included in the breakthrough therapy drug program by the Drug Review Center of the China National Medical Products Administration for the treatment of symptomatic, inoperable neurofibromatosis type 1 (NF1)-related adult plexiform neurofibromas. According to Phase I clinical trial results presented at the 2025 American Society of Clinical Oncology Annual Meeting, TQ-B3234 demonstrated significant activity against NF1-related plexiform neurofibromas, with 96.7% of NF1-PN subjects experiencing tumor shrinkage and 36.7% achieving partial remission. In an exploratory analysis, 100% of cNF patients experienced tumor shrinkage, with the largest reduction reaching 85.2%. https://finance.eastmoney.com/a/202510153535018717.html
- Source: drugdu
- 88
- October 16, 2025
Novo Nordisk and Omeros reach asset purchase and licensing agreement for zaltinibart

On October 15, Novo NordiskNovo Nordisk and Omeros announced a definitive asset purchase and license agreement for zaltinibart (OMS906), a clinical-stage drug candidate for the treatment of rare blood and kidney diseases. Under the terms of the agreement, Novo Nordisk will obtain exclusive development and commercialization rights for zaltinibart for all indications worldwide. Omeros is eligible to receive an upfront payment of US$340 million and near-term milestone payments, with a total of up to US$2.1 billion including potential development and commercial milestones, plus tiered royalties based on net sales. The transaction is expected to close in the fourth quarter of 2025. https://finance.eastmoney.com/a/202510153535182876.html
- Source: drugdu
- 77
- October 16, 2025
New insights into MDMA therapy for PTSD and beyond

A comprehensive peer-reviewed invited review published today in Psychedelics by Dr. Kenji Hashimoto and colleagues (Dr. Mingming Zhao and Dr. Jianjun Yang) synthesizes the evolving landscape of MDMA-assisted psychotherapy, examining robust clinical evidence in treatment-resistant posttraumatic stress disorder while identifying promising applications in autism spectrum disorder, eating disorders, and existential distress. The review traces the complex journey from early therapeutic promise through prohibition to current regulatory challenges, providing critical analysis of safety profiles and novel resilience mechanisms mediated by the gut-brain axis. Bridging seven decades of research The review encompasses MDMA research spanning from its 1912 synthesis at Merck through contemporary Phase III clinical trials. Dr. Hashimoto and colleagues systematically analyze how this distinctive entactogen reverses the serotonin transporter to massively increase synaptic serotonin while simultaneously engaging oxytocin and catecholaminergic pathways. The authors examine 126 primary sources to construct a comprehensive narrative of how MDMA produces its unique prosocial and ...
- Source: drugdu
- 103
- October 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.